Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (331-340 of 361) with videos related to

Pageof 37
Sort By:
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Molecular Cytogenetics|April 4, 2013
Heteromorphic variants of chromosome 9Nadezda Kosyakova, Ani Grigorian, Thomas Liehr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Journal of Medical Genetics|September 29, 2011
Phenotypic spectrum associated with CASK loss-of-function mutationsUte Moog, Kerstin Kutsche, Fanny Kortüm, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Shaji K Kumar, Natalie S Callander, Jens Hillengass, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 4, 2018
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Pageof 37

Showing results (331-340 of 361) with videos related to

Sort By:
Pageof 37
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Molecular Cytogenetics|April 4, 2013
Heteromorphic variants of chromosome 9Nadezda Kosyakova, Ani Grigorian, Thomas Liehr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Journal of Medical Genetics|September 29, 2011
Phenotypic spectrum associated with CASK loss-of-function mutationsUte Moog, Kerstin Kutsche, Fanny Kortüm, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Shaji K Kumar, Natalie S Callander, Jens Hillengass, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 4, 2018
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Pageof 37